Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 14Peritoneal Neoplasms 10Ovarian Neoplasms 8Fallopian Tube Neoplasms 5Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Neoplasm Metastasis 3Appendiceal Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Mesothelioma 2Hyperthermic Intraperitoneal Chemotherapy 2Gastric Adenocarcinoma 2Carcinoma 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Recurrence 1Pseudomyxoma Peritonei 1Peritoneal Diseases 1Malignant Neoplasm of Colorectum 1Locally Advanced Gastric Cancer 1Gastrointestinal Neoplasms 1Gastric Cancer Peritoneal Metastases 1Exploratory Behavior 1Drug-Related Side Effects and Adverse Reactions 1Desmoplastic Small Round Cell Tumor 1Clinical Stage I Gastric Cancer AJCC v8 1

Interventions

Pancreaticoduodenectomy 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1Filgrastim 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peritoneal Diseases × Hyperthermic Intraperitoneal Chemotherapy × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡